Immusoft
Immusoft develops cell therapies that program patients’ own B cells to produce therapeutic proteins for sustained delivery. Its therapies are intended for people with rare and other diseases with significant unmet need.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2009
- Type
- Corporation Seattle business license
- Employees
- 21
- Registered name
- Immusoft Corp Seattle business license
- Stage
- Series B
- Members see funding amounts. .
- Founders
- Matthew Scholz
Is this your organization? Claim it
Immusoft Receives $15M CIRM Grant to Advance ISP-001 Engineered B‑Cell Therapy for MPS I
Immusoft won a $15 million CIRM grant to advance ISP-001, an engineered autologous B‑cell therapy that continuously produces IDUA enzyme for treating MPS I; early Phase 1/2 results show favorable safety, successful re-dosing, and encouraging functional signals in patients. The program aims to address limitations of current MPS I treatments by providing sustained enzyme replacement via patient-derived "living biofactories."
Investor Momentum and New FDA Pathways Propel Rare Disease Drug Market Toward $400–600B by Mid-2030s, Spotlighting Ultrarare Conditions like MPS II
Investor interest, new FDA programs, and advances in cell and gene therapies are driving rapid growth in rare disease drug development, bringing ultrarare conditions like MPS II into focus and positioning the market for large expansion over the next decade.
Immusoft’s ISP Platform Achieves First Redosing of Ex Vivo CGT Without Preconditioning, Advancing ISP-001 in Phase I/IIa for MPS 1
Immusoft’s ISP platform enabled the first redosing of an ex vivo cell & gene therapy without patient preconditioning and is now adjusting doses in a Phase I/IIa trial for MPS 1 (Hurler syndrome). Redosing could let clinicians tailor therapy over time, reduce payer burden by spreading costs, and potentially maintain or restore long-term efficacy where single-dose AAV treatments cannot be repeated.
See all 7 stories, episodes and videos about Immusoft.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Sean Ainsworth Executive, Executive Officer, Director, Chief Executive Officer
-
Scott McIvor Executive, Chief Development Officer